SLC2A1 and osteosarcoma: Additionally, increased GLUT1 expression allows cancer cells to survive low glucose conditions (49), and hypoxic tumor cells are resistant to conventional therapeutics, highlighting the potential of glycolytic inhibitors in osteosarcomas (50).